Plasma Proteomics Analysis for Screening Anlotinib Responders in Non-small Cell Lung Cancer
Background
Anlotinib has been demonstrated to be effective in advanced non-small cell lung cancer (NSCLC) patients. The underlying value of proteomics for anlotinib study remains unclear.
Methods
In this study, plasma samples from 28 anlotinib-treated NSCLC patients (including 14 responders and 14 non-responders) were performed proteomics analysis. LC-MS/MS analysis was performed on those samples with different time points including baseline, best response and progression disease. Bioinformatics analysis was performed to understand the underlying value of those differential proteins.
Results
Proteomics analysis suggested the differential proteins from responders after anlotinib administration potential play a role in the molecular mechanism characterization and biomarker screening. The differential proteins between responders and non-responders at baseline mainly contribute to biomarker screening. Integrative analysis indicated 43 proteins could be used as underlying biomarkers for clinical practice. Lastly, we selected ARHGDIB and demonstrated that it has potential predictive value for anlotinib.
Conclusions
This study not only offered the first insight that the proteomic technology potentially be used for anlotinib molecular mechanism characterization, but also provided a basis for anlotinb biomarker screening via proteomics in the future.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
Posted 12 May, 2020
Plasma Proteomics Analysis for Screening Anlotinib Responders in Non-small Cell Lung Cancer
Posted 12 May, 2020
Background
Anlotinib has been demonstrated to be effective in advanced non-small cell lung cancer (NSCLC) patients. The underlying value of proteomics for anlotinib study remains unclear.
Methods
In this study, plasma samples from 28 anlotinib-treated NSCLC patients (including 14 responders and 14 non-responders) were performed proteomics analysis. LC-MS/MS analysis was performed on those samples with different time points including baseline, best response and progression disease. Bioinformatics analysis was performed to understand the underlying value of those differential proteins.
Results
Proteomics analysis suggested the differential proteins from responders after anlotinib administration potential play a role in the molecular mechanism characterization and biomarker screening. The differential proteins between responders and non-responders at baseline mainly contribute to biomarker screening. Integrative analysis indicated 43 proteins could be used as underlying biomarkers for clinical practice. Lastly, we selected ARHGDIB and demonstrated that it has potential predictive value for anlotinib.
Conclusions
This study not only offered the first insight that the proteomic technology potentially be used for anlotinib molecular mechanism characterization, but also provided a basis for anlotinb biomarker screening via proteomics in the future.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6